Comparative optic and dosimetric characterization of the HYPERSCINT scintillation dosimetry research platform for multipoint applications.

multipoint plastic scintillator detector photodetector photon beam dosimetry

Journal

Physics in medicine and biology
ISSN: 1361-6560
Titre abrégé: Phys Med Biol
Pays: England
ID NLM: 0401220

Informations de publication

Date de publication:
16 04 2021
Historique:
received: 04 11 2020
accepted: 24 03 2021
pubmed: 25 3 2021
medline: 2 10 2021
entrez: 24 3 2021
Statut: epublish

Résumé

This study introduces the HYPERSCINT research platform (HYPERSCINT-RP100, Medscint Inc., Quebec, Canada), the first commercially available scintillation dosimetry platform capable of multi-point dosimetry through the hyperspectral approach. Optic and dosimetric performances of the system were investigated through comparison with another commercially available solution, the Ocean Optics QE65Pro spectrometer. The optical characterization was accomplished by measuring the linearity of the signal as a function of integration time, photon detection efficiency and spectral resolution for both systems under the same conditions. Dosimetric performances were then evaluated with a 3-point plastic scintillator detector (mPSD) in terms of signal to noise ratio (SNR) and signal to background ratio (SBR) associated with each scintillator. The latter were subsequently compared with those found in the literature for the Exradin W1, a single-point plastic scintillator detector. Finally, various beam measurements were realized with the HYPERSCINT platform to evaluate its ability to perform clinical photon beam dosimetry. Both systems were found to be comparable in terms of linearity of the signal as a function of the intensity. Although the QE65Pro possesses a higher spectral resolution, the detection efficiency of the HYPERSCINT is up to 1000 time greater. Dosimetric measurements shows that the latter also offers a better SNR and SBR, surpassing even the SNR of the Exradin W1 single-point PSD. While doses ranging from 1 to 600 cGy were accurately measured within 2.1% of the predicted dose using the HYPERSCINT platform coupled to the mPSD, the Ocean optics spectrometer shows discrepancies up to 86% under 50cGy. Similarly, depth dose, full width at half maximum region of the beam profile and output factors were all accurately measured within 2.3% of the predicted dose using the HYPERSCINT platform and exhibit an average difference of 0.5%, 1.6% and 0.6%, respectively.

Identifiants

pubmed: 33761485
doi: 10.1088/1361-6560/abf1bd
doi:

Substances chimiques

Plastics 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021 Institute of Physics and Engineering in Medicine.

Auteurs

Emilie Jean (E)

Département de Physique, de génie Physique et d'optique et Centre de Recherche sur le Cancer, Université Laval, Quebec, QC, Canada.
Département de radio-oncologie et Axe Oncologie du CRCHU de Québec, CHU de Québec - Université Laval, Quebec, QC, Canada.
Département de radio-oncologie du CIUSSS-MCQ, CHAUR de Trois-Rivières, Trois-Rivières, QC, Canada.

Luc Beaulieu (L)

Département de Physique, de génie Physique et d'optique et Centre de Recherche sur le Cancer, Université Laval, Quebec, QC, Canada.
Département de radio-oncologie et Axe Oncologie du CRCHU de Québec, CHU de Québec - Université Laval, Quebec, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH